1. Home
  2. TSLX vs BEAM Comparison

TSLX vs BEAM Comparison

Compare TSLX & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TSLX
  • BEAM
  • Stock Information
  • Founded
  • TSLX 2010
  • BEAM 2017
  • Country
  • TSLX United States
  • BEAM United States
  • Employees
  • TSLX N/A
  • BEAM N/A
  • Industry
  • TSLX Investment Managers
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TSLX Finance
  • BEAM Health Care
  • Exchange
  • TSLX Nasdaq
  • BEAM Nasdaq
  • Market Cap
  • TSLX 2.2B
  • BEAM 2.3B
  • IPO Year
  • TSLX 2014
  • BEAM 2020
  • Fundamental
  • Price
  • TSLX $21.08
  • BEAM $23.23
  • Analyst Decision
  • TSLX Buy
  • BEAM Strong Buy
  • Analyst Count
  • TSLX 9
  • BEAM 11
  • Target Price
  • TSLX $23.44
  • BEAM $49.40
  • AVG Volume (30 Days)
  • TSLX 578.9K
  • BEAM 2.6M
  • Earning Date
  • TSLX 11-04-2025
  • BEAM 11-04-2025
  • Dividend Yield
  • TSLX 9.64%
  • BEAM N/A
  • EPS Growth
  • TSLX N/A
  • BEAM N/A
  • EPS
  • TSLX 2.04
  • BEAM N/A
  • Revenue
  • TSLX $464,512,000.00
  • BEAM $55,701,000.00
  • Revenue This Year
  • TSLX N/A
  • BEAM N/A
  • Revenue Next Year
  • TSLX N/A
  • BEAM $19.01
  • P/E Ratio
  • TSLX $10.36
  • BEAM N/A
  • Revenue Growth
  • TSLX N/A
  • BEAM N/A
  • 52 Week Low
  • TSLX $18.58
  • BEAM $13.53
  • 52 Week High
  • TSLX $25.17
  • BEAM $35.25
  • Technical
  • Relative Strength Index (RSI)
  • TSLX 33.08
  • BEAM 42.93
  • Support Level
  • TSLX $22.36
  • BEAM $26.90
  • Resistance Level
  • TSLX $23.19
  • BEAM $26.17
  • Average True Range (ATR)
  • TSLX 0.44
  • BEAM 1.84
  • MACD
  • TSLX -0.03
  • BEAM -0.68
  • Stochastic Oscillator
  • TSLX 0.47
  • BEAM 11.47

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: